Zentalis Pharmaceuticals, Inc. (ZNTL)
3.99
-0.12
(-2.92%)
USD |
NASDAQ |
Sep 04, 16:00
3.995
0.00 (0.00%)
After-Hours: 20:00
Zentalis Pharmaceuticals Research and Development Expense (Quarterly) : 35.16M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 35.16M |
| March 31, 2026 | 28.72M |
| December 31, 2025 | 29.49M |
| September 30, 2025 | 22.95M |
| June 30, 2025 | 27.61M |
| March 31, 2025 | 26.10M |
| December 31, 2024 | 32.97M |
| September 30, 2024 | 36.82M |
| June 30, 2024 | 48.39M |
| March 31, 2024 | 49.58M |
| December 31, 2023 | 51.56M |
| September 30, 2023 | 46.76M |
| June 30, 2023 | 42.68M |
| March 31, 2023 | 48.58M |
| December 31, 2022 | 40.62M |
| Date | Value |
|---|---|
| September 30, 2022 | 42.18M |
| June 30, 2022 | 43.82M |
| March 31, 2022 | 46.11M |
| December 31, 2021 | 38.44M |
| September 30, 2021 | 45.20M |
| June 30, 2021 | 44.77M |
| March 31, 2021 | 38.39M |
| December 31, 2020 | 29.52M |
| September 30, 2020 | 24.67M |
| June 30, 2020 | 17.45M |
| March 31, 2020 | 13.26M |
| December 31, 2019 | 11.87M |
| September 30, 2019 | 10.74M |
| June 30, 2019 | 8.689M |
| March 31, 2019 | 7.089M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | 4.698M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |